Draft Guidance Addresses Company Requests For Rationale Of FDA Decisions
This article was originally published in The Gray Sheet
The document offers FDA’s interpretation of the terms “substantive summary” and “significant decisions,” both of which appear in new statutory provisions related to the longstanding process for manufacturers to appeal an agency decision.
You may also be interested in...
A final guidance on so-called 517A requests, in which companies can request a substantive summary of FDA’s rationale for certain decisions, puts an agency halt of a device trial on the list of actions that qualify for such a request. That is a new addition from the 2013 draft version.
FDA’s new draft guidance explains the various routes to appeal a CDRH decision, but doesn’t do much to reform the appeals process, according to one device attorney.